Stock Track | Arcutis Biotherapeutics Soars 5.08% on Strong Earnings and Positive Clinical Updates

Stock Track

Mar 01

Arcutis Biotherapeutics Inc. (ARQT) saw its stock surge 5.08% during Friday's trading session, propelled by the company's impressive quarterly performance and encouraging developments in its drug pipeline.

In its latest earnings report, Arcutis exceeded analyst expectations with a 6% beat on revenue and a narrower-than-expected loss per share. Buoyed by these results, analysts raised their 2025 revenue forecasts for the company by 4.6% to $301.8 million and lowered their projected loss per share by 19% to $0.60.

Adding to the positive sentiment, Arcutis announced that it will present data from two Phase 3 trials of its atopic dermatitis and psoriasis treatments, ZORYVE cream and ZORYVE foam, at the upcoming American Academy of Dermatology annual meeting. The data highlights the products' strong safety and tolerability profiles, as well as improvements in patient-reported outcomes, further bolstering their commercial prospects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1166577550"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1166577550\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1166577550?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-01 04:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1166577550","market":"hk","top_or_hot":-1,"title":"Stock Track | Arcutis Biotherapeutics Soars 5.08% on Strong Earnings and Positive Clinical Updates","media":"Stock Track","content":"<p>Arcutis Biotherapeutics Inc. (ARQT) saw its stock surge 5.08% during Friday's trading session, propelled by the company's impressive quarterly performance and encouraging developments in its drug pipeline.</p>\n\n<p>In its latest earnings report, Arcutis exceeded analyst expectations with a 6% beat on revenue and a narrower-than-expected loss per share. Buoyed by these results, analysts raised their 2025 revenue forecasts for the company by 4.6% to $301.8 million and lowered their projected loss per share by 19% to $0.60.</p>\n\n<p>Adding to the positive sentiment, Arcutis announced that it will present data from two Phase 3 trials of its atopic dermatitis and psoriasis treatments, ZORYVE cream and ZORYVE foam, at the upcoming American Academy of Dermatology annual meeting. The data highlights the products' strong safety and tolerability profiles, as well as improvements in patient-reported outcomes, further bolstering their commercial prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Arcutis Biotherapeutics Soars 5.08% on Strong Earnings and Positive Clinical Updates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Arcutis Biotherapeutics Soars 5.08% on Strong Earnings and Positive Clinical Updates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-03-01 04:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Arcutis Biotherapeutics Inc. (ARQT) saw its stock surge 5.08% during Friday's trading session, propelled by the company's impressive quarterly performance and encouraging developments in its drug pipeline.</p>\n\n<p>In its latest earnings report, Arcutis exceeded analyst expectations with a 6% beat on revenue and a narrower-than-expected loss per share. Buoyed by these results, analysts raised their 2025 revenue forecasts for the company by 4.6% to $301.8 million and lowered their projected loss per share by 19% to $0.60.</p>\n\n<p>Adding to the positive sentiment, Arcutis announced that it will present data from two Phase 3 trials of its atopic dermatitis and psoriasis treatments, ZORYVE cream and ZORYVE foam, at the upcoming American Academy of Dermatology annual meeting. The data highlights the products' strong safety and tolerability profiles, as well as improvements in patient-reported outcomes, further bolstering their commercial prospects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARQT","symbol_name":"Arcutis Biotherapeutics Inc.","start_time":0,"source_url":"","article_id":"1166577550","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1166577550","pubTimestamp":1740775716,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Arcutis Biotherapeutics Inc.  saw its stock surge 5.08% during Friday's trading session, propelled by the company's impressive quarterly performance and encouraging developments in its drug pipeline.In its latest earnings report, Arcutis exceeded analyst expectations with a 6% beat on revenue and a narrower-than-expected loss per share. Buoyed by these results, analysts raised their 2025 revenue forecasts for the company by 4.6% to $301.8 million and lowered their projected loss per share by 19%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARQT":"Arcutis Biotherapeutics Inc."},"translate_title":"Arcutis Biotherapeutics因强劲的盈利和积极的临床更新而飙升5.08%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARQT":1},"content_text":"Arcutis Biotherapeutics Inc. (ARQT) saw its stock surge 5.08% during Friday's trading session, propelled by the company's impressive quarterly performance and encouraging developments in its drug pipeline.\nIn its latest earnings report, Arcutis exceeded analyst expectations with a 6% beat on revenue and a narrower-than-expected loss per share. Buoyed by these results, analysts raised their 2025 revenue forecasts for the company by 4.6% to $301.8 million and lowered their projected loss per share by 19% to $0.60.\nAdding to the positive sentiment, Arcutis announced that it will present data from two Phase 3 trials of its atopic dermatitis and psoriasis treatments, ZORYVE cream and ZORYVE foam, at the upcoming American Academy of Dermatology annual meeting. The data highlights the products' strong safety and tolerability profiles, as well as improvements in patient-reported outcomes, further bolstering their commercial prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}